Publications :: CytoDyn Inc. (CYDY)

For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar

Learn More

Leronlimab a Humanized Anti-CCR5 Monoclonal Antibody Ameliorates Hepatic Fibrosis in Two Preclinical Fibrosis Mouse Models

Leronlimab a Humanized Anti-CCR5 Monoclonal Antibody Ameliorates Hepatic Fibrosis in Two Preclinical Fibrosis Mouse Models

May 1, 2026

Sustained disease-free survival in metastatic triple-negative breast cancer following CCR5 antibody leronlimab and atezolizumab: A case study

Sustained disease-free survival in metastatic triple-negative breast cancer following CCR5 antibody leronlimab and atezolizumab: A case study

May 1, 2026

CytoDyn’s AACR Annual Meeting Poster – Dr. Kasi (April 2026)

CytoDyn’s AACR Annual Meeting Poster – Dr. Kasi (April 2026)

Apr 21, 2026

CytoDyn’s AACR Annual Meeting Poster – Dr. Pestell (April 2026)

CytoDyn’s AACR Annual Meeting Poster – Dr. Pestell (April 2026)

Apr 19, 2026

CytoDyn’s AACR Special Conference in Cancer Research: Brain Cancer Poster (March 2026)

CytoDyn’s AACR Special Conference in Cancer Research: Brain Cancer Poster (March 2026)

Mar 23, 2026

CytoDyn’s AACR IO Poster (February 2026)

CytoDyn’s AACR IO Poster (February 2026)

Feb 19, 2026

CytoDyn’s SABCS Poster (2025)

CytoDyn’s SABCS Poster (2025)

Dec 12, 2025

A Proof-of-Concept Phase 2a Partly Randomised Study Evaluating Leronlimab in Patients With Presumed Non-Cirrhotic Metabolic Dysfunction–Associated Steatohepatitis

A Proof-of-Concept Phase 2a Partly Randomised Study Evaluating Leronlimab in Patients With Presumed Non-Cirrhotic Metabolic Dysfunction–Associated Steatohepatitis

Oct 14, 2025

CytoDyn’s ESMO GI Poster (2025)

CytoDyn’s ESMO GI Poster (2025)

Jul 4, 2025

CytoDyn’s ESMO Breast Cancer Poster (2025)

CytoDyn’s ESMO Breast Cancer Poster (2025)

May 15, 2025

1
2
3
Next »